Wolfe Research Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Merck & Co., Inc. (NYSE:MRK) had its price objective upped by analysts at Wolfe Research from $155.00 to $180.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wolfe Research’s price target would suggest a potential upside of 17.00% from the company’s current price.

A number of other equities research analysts have also issued reports on MRK. BMO Capital Markets raised their price target on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, August 20th. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Finally, Bank of America upped their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $147.60.

Merck & Co., Inc. Trading Up 2.1%

Shares of Merck & Co., Inc. stock traded up $3.19 during trading on Tuesday, hitting $153.85. The stock had a trading volume of 3,201,016 shares, compared to its average volume of 10,838,494. The firm’s fifty day simple moving average is $128.81 and its 200-day simple moving average is $121.53. The stock has a market cap of $379.57 billion, a PE ratio of 123.46, a PEG ratio of 6.40 and a beta of 0.19. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $155.10.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Insider Activity at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 52,847 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock worth $29,977,783 over the last quarter. Corporate insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its position in Merck & Co., Inc. by 12,537.4% during the 2nd quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company’s stock valued at $62,286,552,000 after acquiring an additional 480,884,635 shares in the last quarter. Norges Bank bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth $3,997,933,000. Wellington Management Group LLP lifted its stake in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares during the last quarter. Cardano Risk Management B.V. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $1,012,530,000. Finally, Jennison Associates LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth $585,192,000. Institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Argus raised its price target to $170 and upgraded Merck to “Buy,” up from a $145 target. The new target implies roughly 11% upside from the referenced price and reinforces growing Wall Street confidence in Merck’s outlook. Tickerreport.com article
• Positive Sentiment: Positive Phase 3 results from Merck and Moderna’s INTerpath-001 trial showed that the personalized neoantigen therapy intismeran autogene, used with Merck’s Keytruda, cleared a major hurdle in resected melanoma. The results strengthen expectations for a potentially meaningful expansion of Keytruda’s cancer franchise and helped add billions to Merck’s market value. TheStreet article
• Positive Sentiment: The cancer-vaccine data also improved investor confidence in Moderna’s messenger-RNA platform and related personalized cancer treatments, indirectly highlighting the strategic value of Merck’s collaboration and Keytruda combination. Moderna and Merck Cancer Vaccine Success article
• Neutral Sentiment: Market commentary points to a possible rotation away from technology stocks and toward other sectors. That environment may favor relatively defensive large-cap healthcare companies such as Merck, although the broader market shift is not specific to MRK. Jim Cramer market rotation article
• Neutral Sentiment: Merck’s recent move to annual highs reflects a combination of favorable company catalysts and Wall Street price-target increases, but profit-taking across biotechnology shares and mixed market sentiment could contribute to near-term volatility. Stocktwits article

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.